Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have received a consensus rating of “Hold” from the six analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $51.75.

Several equities analysts have recently weighed in on the stock. Ascendiant Capital Markets cut their target price on shares of Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating for the company in a report on Monday, June 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a report on Friday, July 17th.

Plus Therapeutics Trading Down 2.1%

Shares of PSTV stock opened at $3.02 on Friday. The stock has a 50 day moving average of $3.79 and a 200 day moving average of $5.25. The stock has a market cap of $20.79 million, a P/E ratio of -1.31 and a beta of 1.40. Plus Therapeutics has a twelve month low of $2.90 and a twelve month high of $23.42.

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.43). Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. The company had revenue of $0.41 million during the quarter, compared to analyst estimates of $1.11 million. On average, research analysts predict that Plus Therapeutics will post -3.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Plus Therapeutics

Several hedge funds have recently modified their holdings of the company. L1 Global Manager Pty Ltd purchased a new position in shares of Plus Therapeutics in the 4th quarter valued at about $1,167,000. Geode Capital Management LLC boosted its position in Plus Therapeutics by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after purchasing an additional 589,544 shares in the last quarter. Jane Street Group LLC purchased a new position in Plus Therapeutics during the fourth quarter worth approximately $525,000. Virtu Financial LLC acquired a new stake in Plus Therapeutics in the fourth quarter valued at approximately $254,000. Finally, State Street Corp grew its holdings in Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after purchasing an additional 127,000 shares during the period. 3.28% of the stock is owned by hedge funds and other institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.